Figure 2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Year: 2024
Type: other
Abstract: Key secondary endpoints. Key secondary endpoints include rPFS, OS, duration of PSA response, and quality of life measured using the FACT-P instrument. A, rPFS and (B) OS are presented for docetaxel + HDIVC vs. docetaxel + placebo. The KM method was used to estimate the median, 12-month, and 24-month rates of rPFS and OS. C, Duration of PSA response and (D) FACT-P scores are presented for docetaxel + HDIVC vs. docetaxel + placebo.
Authors: Channing J. Paller, Marianna L. Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth Heath, William K. Kelly, Christopher Hoimes, Pedro Barata, Jason Taksey, Dominique A. Garrison, Kartick Patra, Ginger L. Milne, Nicole M. Anders, Julie M. Nauroth, Jennifer N. Durham, Catherine H. Marshall, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Michael A. Carducci, Samuel R. Denmeade, Mark Levine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402159288